HoldingsChannel.com
ONCT insider buying image
The table below summarizes the most recent ONCT insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why ONCT insider buys are important for investors to follow.
DateInsiderPriceAmount
4-8-2024
Insider Buy
Robert James Wills
Director
$8.96
CAGR »
$27,654.57
3,086 shares
3-28-2024
Insider Buy
Robert James Wills
Director
$8.48
CAGR »
$58,602.37
6,914 shares
2-23-2024
Insider Buy
David F. Hale
Director
$9.04
CAGR »
$8,859.20
980 shares
6-14-2023
Insider Buy
Gunnar F. Kaufmann
Chief Scientific Officer
$0.35
CAGR »
$9,824.10
28,000 shares
4-14-2023
Insider Buy
James B. Breitmeyer
Chief Executive Officer
$0.29
CAGR »
$43,929.75
150,000 shares
4-14-2023
Insider Buy
Salim Yazji
Chief Medical Officer
$0.29
CAGR »
$7,200.00
25,000 shares
4-13-2023
Insider Buy
Richard G. Vincent
Chief Financial Officer
$0.30
CAGR »
$8,961.00
30,000 shares
4-13-2023
Insider Buy
Chase C. Leavitt
General Counsel/Secretary
$0.29
CAGR »
$7,250.00
25,000 shares
3-28-2022
Insider Buy
Richard G. Vincent
Chief Financial Officer
$1.44
CAGR »
$7,210.38
5,000 shares
7-21-2020
Insider Buy
Shanghai Pharmaceutical (USA) Inc.
>10% Owner
$2.38
CAGR »
$2,499,997.75
1,049,317 shares

Also See: Institutional Holders of ONCT
Also See: SEC filings

ONCT Performance Since Insider Purchase
Below we present the annualized performance delivered by ONCT stock since 4-8-2024 (the date of the most recent insider purchase). The performance of the investment from the time ONCT insider buying occurred is the ultimate test of whether insiders were right about ONCT being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/09/2024
End date: 04/30/2024
Start price/share: $8.62
End price/share: $8.31
Dividends collected/share: $0.00
Total return: -3.60%
Annualized Gain: -62.51%
Starting investment: $10,000.00
Ending investment: $9,640.00
Years: 0.06

ONCT Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent ONCT insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding ONCT

Quotes delayed 20 minutes

Email EnvelopeFree ONCT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the ONCT Insider Buying occurred are:

MXC Insider Buying
MMLP Insider Buying
ALRN Insider Buying
DOMH Insider Buying
TRDA Insider Buying
BRTX Insider Buying
ANNX Insider Buying
HRTG Insider Buying
NXMH Insider Buying
ALIT Insider Buying

ONCT Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2024, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.